drugset / Trial / NCT01378533

The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC

NCT01378533

Phase 3 Unknown 100 enrolled Chinese Academy of Medical Sciences
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this trial is to compare the 3 years DFS of dose-dense epirubicin and cyclophosphamide followed by paclitaxel with paclitaxel plus carboplatin as adjuvant therapy for triple-negative breast cancer. The other purpose of this trial is to observe the patient's tolerance.

Timeline

Start
2011-05
Primary completion
2013-05
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 3 unknown Intravenous
Subject Cyclophosphamide Other / unclassified 600 mg/m2 Intravenous
Subject Epirubicin Small molecule 80 mg/m2 Intravenous
Subject Paclitaxel Small molecule 150 mg/m2 Intravenous
Subject Paclitaxel Small molecule 175 mg/m2 Intravenous

Indications